Alps Advisors Inc Vaxart, Inc. Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $12,479 - $26,869	-5,971 Reduced 7.96%	69,043 $151,000
Q2 2022 Aug 11, 2022	BUY	$2.7 - $5.28 $202,537 - $396,073	75,014 New	75,014 $263,000
Q1 2022 May 16, 2022	SELL	$4.29 - $6.64 $621,929 - $962,614	-144,972 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$5.77 - $7.96 $836,488 - $1.15 Million	144,972 New	144,972 $909,000
Q2 2021 Aug 11, 2021	SELL	$5.06 - $10.78 $1 Million - $2.14 Million	-198,053 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$5.64 - $23.33 $3,773 - $15,607	669 Added 0.34%	198,053 $1.2 Million
Q4 2020 Feb 03, 2021	BUY	$3.5 - $7.98 $690,844 - $1.58 Million	197,384 New	197,384 $1.13 Million

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.